PERCEPTIVE ADVISORS LLC
NEW YORK, NY · CIK 1224962 · 13F filing filed 2023-08-24
SEC-registered investment adviser since 2010 · limited liability company
- Assets managed$11.8bn
- Staff49 · 28 in investment roles
- Main clients (by assets)Private funds 99%
- Private funds17 (6 hedge) · $11.7bn gross assets
- Form ADV · 2026-07-13SEC adviser record
- Legal entityPERCEPTIVE ADVISORS LLC (US)
- Kindhedge funds, private equity, venture, futures
- Others nearbyNew York, NY, Greenwich, CT, Miami Beach, FL, Sheridan, WY, Water Mill, NY
As an employer
- Offices in1 country
- Private fundshedge 6, venture capital 2, private equity 5, other private 4
Where they work
Offices
From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.
| City | People |
|---|---|
| New York, NY (main office)United States | about 25 |
| Greenwich, CTUnited States | 1 |
| Miami Beach, FLUnited States | 1 |
| Sheridan, WYUnited States | 1 |
| Water Mill, NYUnited States |
Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.
Options: 3 call positions ($1.4m notional), 4 put positions ($11.6m notional) – listed below, not included above.
Holdings, Q2 2023
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| AMICUS THERAPEUTICS INC FOLD | $347.4m10.09% | Unchanged |
| CEREVEL THERAPEUTICS HLDNG I CERE | $320.7m9.32% | Added +3.6m |
| LIANBIO LIANY | $131.2m3.81% | Unchanged |
| ARCELLX INC ACLX | $127.0m3.69% | Added +174.7k |
| AMYLYX PHARMACEUTICALS INC AMLX | $105.1m3.05% | Reduced -1.2m |
| IOVANCE BIOTHERAPEUTICS INC IOVA | $98.8m2.87% | Reduced -1.3m |
| ALDEYRA THERAPEUTICS INC ALDX | $95.2m2.77% | Unchanged |
| INHIBRX INC INBX | $94.1m2.73% | Added +8.8k |
| VERONA PHARMA PLC VRNA | $93.0m2.70% | Added +1.7m |
| NUVALENT INC COM | $92.6m2.69% | Reduced -105.2k |
| AKERO THERAPEUTICS INC AKRO | $90.6m2.63% | Added +1.4m |
| VAXCYTE INC PCVX | $80.6m2.34% | Added +444.1k |
| MEIRAGTX HLDGS PLC MGTX | $76.1m2.21% | Added +4.4m |
| APELLIS PHARMACEUTICALS INC APLS | $74.0m2.15% | Added +256.7k |
| MADRIGAL PHARMACEUTICALS INC MDGL | $70.0m2.03% | Reduced -347.6k |
| REATA PHARMACEUTICALS INC RETA | $68.3m1.99% | Reduced -1.5m |
| TREACE MED CONCEPTS INC TMCI | $56.7m1.65% | Reduced -225.0k |
| LYRA THERAPEUTICS INC LYRA | $52.4m1.52% | Added +3.6m |
| VIR BIOTECHNOLOGY INC VIR | $48.0m1.40% | Added +1.8m |
| IMMUNOVANT INC IMVT | $47.9m1.39% | Added +1.2m |
| XENON PHARMACEUTICALS INC XENE | $47.1m1.37% | Reduced -608.8k |
| ADMA BIOLOGICS INC ADMA | $43.9m1.28% | Unchanged |
| RAPT THERAPEUTICS INC COM | $42.8m1.24% | Reduced -3.1k |
| VIRIDIAN THERAPEUTICS INC VRDN | $42.3m1.23% | Added +40.0k |
| MEDTRONIC PLC MDT | $41.1m1.20% | New |
| CYMABAY THERAPEUTICS INC CBAY | $40.9m1.19% | Reduced -170.0k |
| PROTAGONIST THERAPEUTICS INC PTGX | $40.6m1.18% | Added +504.6k |
| SPRINGWORKS THERAPEUTICS INC SWTX | $40.3m1.17% | Reduced -541.9k |
| IMMATICS N.V IMTX | $40.3m1.17% | Unchanged |
| ACRIVON THERAPEUTICS INC ACRV | $39.0m1.13% | Unchanged |
| NAUTILUS BIOTECHNOLOGY INC NAUT | $35.3m1.02% | Unchanged |
| CRINETICS PHARMACEUTICALS IN CRNX | $35.1m1.02% | Reduced -1.6m |
| DISC MEDICINE INC IRON | $33.0m0.96% | New |
| ROIVANT SCIENCES LTD ROIV | $31.6m0.92% | Added +439.6k |
| COGENT BIOSCIENCES INC COGT | $31.5m0.91% | Added +377.1k |
| HARMONY BIOSCIENCES HLDGS IN HRMY | $31.4m0.91% | Added +791.4k |
| BRIDGEBIO PHARMA INC BBIO | $30.1m0.87% | Reduced -158.1k |
| ESTABLISHMENT LABS HLDGS INC ESTA | $29.2m0.85% | Reduced -42.9k |
| VERRICA PHARMACEUTICALS INC COM | $29.1m0.84% | Unchanged |
| ILLUMINA INC ILMN | $27.2m0.79% | New |
| ARGENX SE ARGX | $26.9m0.78% | New |
| MIRATI THERAPEUTICS INC MRTX | $26.0m0.75% | Reduced -855.0k |
| RELAY THERAPEUTICS INC RLAY | $24.4m0.71% | Unchanged |
| TARSUS PHARMACEUTICALS INC TARS | $23.4m0.68% | Unchanged |
| ROCKET PHARMACEUTICALS INC RCKT | $23.2m0.67% | Added +300.6k |
| BIOMARIN PHARMACEUTICAL INC BMRN | $22.8m0.66% | Reduced -409.9k |
| ZYMEWORKS INC ZYME | $20.9m0.61% | Reduced -962.3k |
| CABALETTA BIO INC CABA | $19.9m0.58% | Added +820.2k |
| OUTSET MED INC OM | $19.7m0.57% | Reduced -187.1k |
| NATERA INC NTRA | $19.7m0.57% | Reduced -301.9k |
| AXSOME THERAPEUTICS INC AXSM | $19.5m0.57% | New |
| SOLID BIOSCIENCES INC SLDB | $18.3m0.53% | Unchanged |
| ASTRIA THERAPEUTICS INC CATB | $18.2m0.53% | Unchanged |
| ARTIVION INC AORT | $16.0m0.47% | Reduced -154.5k |
| BIOMEA FUSION INC BMEA | $15.7m0.46% | Added +391.4k |
| INTRA-CELLULAR THERAPIES INC ITCI | $15.6m0.45% | New |
| MIRUM PHARMACEUTICALS INC MIRM | $15.6m0.45% | Unchanged |
| TACTILE SYS TECHNOLOGY INC TCMD | $15.0m0.44% | Reduced -37.5k |
| ORCHESTRA BIOMED HLDGS INC OBIO | $14.4m0.42% | Reduced -225.4k |
| ATHIRA PHARMA INC COM | $14.2m0.41% | Unchanged |
| AXOGEN INC AXGN | $13.4m0.39% | Added +55.0k |
| FUSION PHARMACEUTICALS INC COM | $12.8m0.37% | Reduced -8.5k |
| PROTHENA CORP PLC PRTA | $12.6m0.37% | Reduced -53.0k |
| CAREMAX INC COM CL A | $11.9m0.34% | Added +241.4k |
| SOLENO THERAPEUTICS INC SLNO | $9.5m0.28% | New |
| NEUROCRINE BIOSCIENCES INC NBIX | $9.4m0.27% | Unchanged |
| SAREPTA THERAPEUTICS INC SRPT | $9.3m0.27% | Reduced -179.8k |
| BIOHAVEN LTD BHVN | $7.7m0.22% | New |
| VIKING THERAPEUTICS INC VKTX | $7.2m0.21% | Reduced -430.6k |
| X4 PHARMACEUTICALS INC COM | $6.9m0.20% | Reduced -1.0m |
| IVERIC BIO INC OPHT | $6.6m0.19% | Reduced -332.0k |
| LANDOS BIOPHARMA INC COM NEW | $6.3m0.18% | New |
| TYRA BIOSCIENCES INC TYRA | $6.1m0.18% | Reduced -134.4k |
| NANOBIOTIX NBTX | $5.4m0.16% | Unchanged |
| VBI VACCINES INC CDA VAC | $4.5m0.13% | New |
| ACELYRIN INC COM | $4.2m0.12% | New |
| SOMALOGIC INC SLGC | $3.5m0.10% | Unchanged |
| KRONOS BIO INC KRON | $3.0m0.09% | Unchanged |
| QUANTERIX CORP QTRX | $2.9m0.09% | Unchanged |
| ENVVENO MEDICAL CORPORATION COM | $2.4m0.07% | Unchanged |
| SINGULAR GENOMICS SYSTEMS IN COM | $2.0m0.06% | Reduced -919.1k |
| LEAP THERAPEUTICS INC CYPH | $1.8m0.05% | New |
| TRAVERE THERAPEUTICS INC TVTX | $1.4m0.04% | Unchanged |
| VERU INC COM | $107.0k0.00% | Reduced -4.2m |
| MOTUS GI HLDGS INC COM NEW | $60.3k0.00% | Unchanged |
| EQRX INC *W EXP 12/17/202 | $42.5k0.00% | Unchanged |
| CAREMAX INC *W EXP 06/08/202 | $23.4k0.00% | Unchanged |
| SURROZEN INC *W EXP 08/01/203 | $10.0k0.00% | Unchanged |
Sold out since Q1 2023
| Security | Value then |
|---|---|
| PROMETHEUS BIOSCIENCES INC | $136.6m1.3m shares |
| SANOFI SNY | $41.8m768.1k shares |
| BELLUS HEALTH INC NEW BLU | $35.7m5.0m shares |
| TERNS PHARMACEUTICALS INC | $16.0m1.4m shares |
| VBI VACCINES INC CDA | $15.9m52.3m shares |
| RAIN ONCOLOGY INC | $14.4m1.6m shares |
| INTUITIVE SURGICAL INC ISRG | $12.8m50.0k shares |
| CYTEK BIOSCIENCES INC CTKB | $11.9m1.3m shares |
| LARIMAR THERAPEUTICS INC LRMR | $10.3m2.3m shares |
| MORPHIC HLDG INC MORF | $9.7m256.7k shares |
| BELLEROPHON THERAPEUTICS INC BLPH | $7.3m930.0k shares |
| HILLEVAX INC | $6.7m406.0k shares |
| AVADEL PHARMACEUTICALS PLC | $5.4m590.0k shares |
| LANDOS BIOPHARMA INC | $4.4m14.9m shares |
| ADC THERAPEUTICS SA ADCT | $2.9m1.5m shares |
| PHENOMEX INC BLI | $2.9m2.5m shares |
| LEAP THERAPEUTICS INC LPTX | $2.3m6.7m shares |
| DARIOHEALTH CORP DRIO | $1.3m313.9k shares |
| CLOVER HEALTH INVESTMENTS CO CLOV | $1.3m1.5m shares |
| ATHENEX INC | $1.0m776.6k shares |
| PROTARA THERAPEUTICS INC TARA | $907.9k290.1k shares |
| PEAR THERAPEUTICS INC | $229.6k900.5k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| TERNS PHARMACEUTICALS INC Put | $9.4m1.1m shares | New |
| ARCUTIS BIOTHERAPEUTICS INC ARQT · Put | $1.4m300.0k shares | New |
| MIRATI THERAPEUTICS INC MRTX · Call | $690.0k200.0k shares | New |
| VERONA PHARMA PLC VRNA · Call | $675.0k500.0k shares | New |
| POINT BIOPHARMA GLOBAL INC Put | $675.0k500.0k shares | New |
| SPDR SER TR XBI · Put | $137.5k150.0k shares | Added |
| BIOXCEL THERAPEUTICS INC Call | $11.0k439.5k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on. The largest 25 of 38.
| Company | Stake |
|---|---|
| ADAGIO MED HLDGS INC ADGM · 13G · filed 2026-05-15 | 55.4%≈ $8.8m |
| LEONABIO INC LONA · 13D · filed 2026-10-26 | 20.0%≈ $17.4m |
| LYRA THERAPEUTICS INC LYRA · 13D · filed 2025-08-14 | 15.6% |
| MEIRAGTX HLDGS PLC MGTX · 13D · filed 2026-04-24 | 12.6%≈ $158.6m |
| SOLID BIOSCIENCES INC SLDB · 13D · filed 2026-08-14 | 11.2%≈ $120.3m |
| PERCEPTIVE CAP SOLUTIONS COR FRNM · 13G · filed 2026-07-23 | 10.1% |
| INHIBRX BIOSCIENCES INC INBX · 13G · filed 2026-08-14 | 10.0%≈ $141.1m |
| ALTO NEUROSCIENCE INC ANRO · 13G · filed 2026-08-14 | 10.0%≈ $110.2m |
| OPUS GENETICS INC IRD · 13G · filed 2026-08-14 | 10.0%≈ $37.6m |
| ENGENE HOLDINGS INC 13G · filed 2026-08-14 | 10.0% |
| KIORA PHARMACEUTICALS INC KPRX · 13G · filed 2026-08-10 | 10.0%≈ $1.2m |
| ENVVENO MEDICAL CORPORATION 13G · filed 2026-02-17 | 10.0% |
| ORCHESTRA BIOMED HLDGS INC OBIO · 13G · filed 2025-11-14 | 10.0%≈ $24.5m |
| TRINITY BIOTECH PLC 13D · filed 2026-05-04 | 9.9% |
| OUTSET MED INC OM · 13G · filed 2025-02-28 | 9.5% |
| NAUTILUS BIOTECHNOLOGY INC NAUT · 13D · filed 2026-08-14 | 9.1%≈ $21.8m |
| KARDIGAN INC KARD · 13D · filed 2026-10-01 | 8.8%≈ $196.9m |
| QUINCE THERAPEUTICS INC IRLA · 13G · filed 2026-10-14 | 8.4%≈ $1.7m |
| RESEARCH ALLIANCE CORP III RACC · 13G · filed 2026-05-28 | 8.2%≈ $8.0m |
| X4 PHARMACEUTICALS INC XFOR · 13G · filed 2026-08-14 | 8.1%≈ $37.8m |
| SUTRO BIOPHARMA INC STRO · 13G · filed 2026-08-14 | 7.9%≈ $43.3m |
| PALISADE BIO INC PALI · 13G · filed 2026-05-15 | 7.9%≈ $29.5m |
| IMMATICS N.V IMTX · 13D · filed 2026-08-27 | 7.6%≈ $113.5m |
| AMYLYX PHARMACEUTICALS INC AMLX · 13G · filed 2026-05-15 | 7.5%≈ $148.8m |
| SAB BIOTHERAPEUTICS INC SABS · 13G · filed 2026-08-14 | 7.3%≈ $25.8m |
Trades reported as a company insider in Q2 2023
Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.
| Date | Company | Trade | Value |
|---|---|---|---|
| 2023-05-05 | MEIRAGTX HLDGS PLC Director · See Footnote | Bought | $25.0m4.3m shares |